{"id":"W2313134734","doi":"10.1097/01.cot.0000289678.00323.68","title":"ODAC Votes to Approve Erlotinib (Tarceva) for New Indication","year":2005,"lang":"en","type":"article","venue":"Oncology Times","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Gemcitabine; Medicine; Pancreatic cancer; Internal medicine; Oncology; Clinical trial; Cancer; EGFR inhibitors; Erlotinib Hydrochloride; Gefitinib; Epidermal growth factor receptor","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003755737,0.0006106173,0.0008285993,0.0008546521,0.002688917,0.004687712,0.001546846,0.0122661,0.06070008],"category_scores_gemma":[0.007331473,0.0003338477,0.0014204,0.000685842,0.001139895,0.001791278,0.001325801,0.01068185,0.0369254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003160641,"about_ca_system_score_gemma":0.00806386,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0102962,"about_ca_topic_score_gemma":0.02424208,"domain_scores_codex":[0.9956775,0.0004055925,0.0002378266,0.0004748127,0.002322753,0.0008814472],"domain_scores_gemma":[0.9930238,0.0004892203,0.0002122493,0.0002342803,0.003622323,0.002418143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005243928,0.00002287706,0.0002399489,0.0000157516,0.000003913542,0.0000740915,0.00000656051,0.00001215038,0.0001420524,0.0008568849,0.9901812,0.008392105],"study_design_scores_gemma":[0.00005700592,0.00002179614,0.0004860071,0.00003229899,0.000005544731,0.00009150198,0.00002629541,0.0000404298,0.0001201632,0.000326319,0.9987845,0.000008062536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.003226807,0.008060071,0.001030986,0.6236609,0.1168007,0.0003377938,0.002835045,0.000652151,0.2433956],"genre_scores_gemma":[0.01609066,0.00397409,0.001381278,0.5865148,0.02499934,0.0001416042,0.002639928,0.0003285699,0.3639297],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.06070008,"threshold_uncertainty_score":0.203062,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04608061756976181,"score_gpt":0.4004743114778221,"score_spread":0.3543936939080603,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}